Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary

Aura Biosciences (NASDAQ: AURA) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. CEO Elisabet de los Pinos will engage in a fireside chat on December 3, 2024, at 2:35 p.m. ET. The clinical-stage biotechnology company, which focuses on developing precision therapies for solid tumors, will make the presentation available via live webcast on their investor relations website. A replay will be accessible for 90 days after the event.

News Market Reaction – AURA

+0.90%

+0.90% Session move

In the trading session that priced this news, AURA gained 0.90%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 2:35 p.m. ET.

The live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.

For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.

Investor Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com

Media Contact:
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744

FAQ

When is Aura Biosciences (AURA) presenting at the Evercore ISI HealthCONx Conference 2024?

Aura Biosciences (AURA) will present at the Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 2:35 p.m. ET.

How long will the replay of Aura Biosciences' (AURA) Evercore conference presentation be available?

The webcast replay will be archived and available for 90 days following the presentation date on Aura Biosciences' investor relations website.

What type of therapies is Aura Biosciences (AURA) developing?

Aura Biosciences is developing precision therapies for solid tumors designed to preserve organ function.

Where can I watch Aura Biosciences' (AURA) Evercore conference presentation?

The live webcast will be available on Aura Biosciences' website under the 'Investors & Media' page in the 'Events & Presentations' section at ir.aurabiosciences.com.